СОВРЕМЕННЫЙ ПОДХОД В ЛЕЧЕНИИ ОСТРОГО ТРОМБОЗА ГЛУБОКИХ ВЕН ПРЕПАРАТОМ РИВАРОКСАБАН

Abstract

Aim of prospective clinical study was to evaluate effectiveness, safety and convenience of treatment deep vein thrombosis with oral anticoagulant — Rivaroxaban from the 1st day of treatment. Study population: patients with verified acute deep vein thrombosis admitted to surgery clinic. 39 patients were included in study. Treatment: from the 1st day — Rivaroxaban 15 mg twice a day for period of three weeks, then 20 mg daily. Full treatment period was 3 months for distal vein thrombosis, 6 months for proximal vein thrombosis, 12 months for idiopathic, recidivous deep vein thrombosis and in case of deep vein thrombosis in patients with oncology. For the all period of treatment there were no recurrence, progression of deep vein thrombosis, hemorrhagic ccomplications and pulmonary embolism. Results of this study show, that Rivaroxaban is well tolerated and well compline drug for such type of patients.

Keywords

• deep vein thrombosis
• oral anticoagulant
• pulmonary embolism
• rivaroxaban